PharmaCyte Biotech shares surge 62.68% intraday on FDA approval excitement and cancer therapy advancements.

PharmaCyte Biotech surged 62.68% intraday after announcing FDA approval excitement and monetizing its stake in Femasys Inc., which boosted cash reserves to $20M from $13.3M. The move validated the company’s strategic capital deployment, enhancing liquidity and strengthening its balance sheet. Despite reporting a $8.36M net loss and negative operating income, the significant cash infusion and improved quick ratio of 12.7 signaled short-term resilience, fueling speculative optimism. The rally reflects investor confidence in PharmaCyte’s ability to leverage liquidity for future projects or operational expansion amid biotech sector volatility.